Changes for page Mirati Therapeutics

Last modified by Asif Farooqui on 2021/01/20 06:45
From version < 1.2 >
edited by Asif Farooqui
on 2019/11/26 05:28
To version < 1.3 >
edited by Asif Farooqui
on 2019/11/26 05:28
< >
Change comment: There is no comment for this version

Summary

Details

Page properties
Content
... ... @@ -2,10 +2,8 @@
2 2  {{toc/}}
3 3  {{/box}}
4 4  
5 -= Paragraph 1 =
5 += Overview =
6 6  
7 -==== Overview ====
8 -
9 9  Mirati Therapeutics, Inc. is a clinical-stage oncology company developing product candidates to address the genetic, epigenetic and immunological promoters of cancer. The company's precision oncology clinical programs utilize next-generation genomic testing to identify and select cancer patients who are most likely to benefit from targeted drug treatment. In immuno-oncology, Mirati Therapeutics is advancing clinical programs where the ability of its product candidates to improve the immune environment of tumor cells may enhance and expand the efficacy of existing cancer immunotherapy medicines when given in combination. The company's preclinical programs include potentially first-in-class and best-in-class product candidates specifically designed to address mutations and tumors where few treatment options exist. The company approach each of its discovery and development programs with a singular focus: to translate its deep understanding of the molecular drivers of cancer into better therapies and better outcomes for patients.
10 10  
11 11  The company's clinical pipeline consists of two clinical-stage product candidates: sitravatinib and mocetinostat. The company also have a KRAS inhibitor program in preclinical development. The company's clinical and preclinical programs are summarized in the chart below:
... ... @@ -142,3 +142,5 @@
142 142  ==== Liquidity Overview ====
143 143  
144 144  At March 31, 2018, the company had $148.7 million of cash, cash equivalents and short-term investments compared to $150.8 million at December 31, 2017. In January 2018 the company received an upfront fee of $10.0 million in connection with the BeiGene Agreement. Mirati Therapeutics has not generated any revenue from product sales. To date, Mirati Therapeutics has funded its operations primarily through the sale of its common stock and pre-funded warrants to purchase its common stock and through up-front payments, research funding and milestone payments under collaborative arrangements. To fund future operations, the company will likely need to raise additional capital.
143 +
144 += References =
This site is funded and maintained by Fintel.io